Common Adverse Events to Immunotherapies in mNSCLC

Video

A lung cancer expert describes the common adverse events he sees with immunotherapy in mNSCLC, and the available management strategies.

Related Videos
Video 3 - "Phase 2 Nivo/Cabo in Non-Clear Cell Renal Cell Carcinoma"
Video 2 - "KEYNOTE B61 Extended Follow Up of Lenvatinib plus Pembrolizumab in nccRCC 1L"
Video 1 - "Overview of Non-Clear Cell Renal Cell Carcinoma"
Related Content